Mallory Rice
Family · Auburn, ALNPI 1447816285
Payments from drug & device makers
Across 145 payments — averaging $27.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$476
- Novo Nordisk$338
- GSK$327
- Otsuka America Pharmaceutical, Inc.$193
- Amgen$168
- plus $1K from 21 others
What the payments were for
- Food & beverage$4,021100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 30 | $1,345 |
| AbbVie | 23 | $476 |
| Novo Nordisk | 13 | $338 |
| GSK | 9 | $327 |
| Otsuka America Pharmaceutical, Inc. | 5 | $193 |
| Amgen | 4 | $168 |
| Pfizer | 8 | $138 |
| Lilly USA, LLC | 8 | $121 |
| Johnson & Johnson | 1 | $120 |
| Paratek Pharmaceuticals, Inc. | 2 | $111 |
| Corium, LLC | 8 | $91 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $81 |
| Exact Sciences | 5 | $80 |
| Idorsia Pharmaceuticals US Inc | 5 | $76 |
| Inspire Medical Systems, Inc. | 2 | $66 |
| Bayer | 3 | $52 |
| Phathom Pharmaceuticals, Inc. | 4 | $46 |
| Radius Health, Inc. | 2 | $39 |
| Nestle Healthcare Nutrition Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Corcept Therapeutics | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Merck | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Akebia Therapeutics Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,021 in reported general payments places this provider in the 85th percentile of 3,415 family providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 135 | $170,980 |
| EliquisApixaban | 149 | $125,318 |
| FarxigaDapagliflozin Propanediol | 79 | $52,889 |
| MounjaroTirzepatide | 43 | $49,386 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $37,234 |
| MyrbetriqMirabegron | 54 | $36,734 |
| JardianceEmpagliflozin | 23 | $32,809 |
| LinzessLinaclotide | 45 | $31,600 |
| JanuviaSitagliptin Phosphate | 47 | $27,955 |
| Breo ElliptaFluticasone/Vilanterol | 58 | $26,437 |
| EntrestoSacubitril/Valsartan | 21 | $22,494 |
| CreonLipase/Protease/Amylase | 13 | $15,432 |
| Levothyroxine Sodium | 547 | $9,032 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $8,429 |
| VascepaIcosapent Ethyl | 24 | $8,257 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $338 | $170,980135 claims |
| PfizerEliquis | $138 | $125,318149 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $327 | $63,671113 claims |
| AstraZenecaFarxiga, Brilinta | $1,345 | $59,24094 claims |
| AbbVieLinzess, Creon, Synthroid | $476 | $52,524111 claims |
| Lilly USA, LLCMounjaro | $121 | $49,38643 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $36,73454 claims |
| MerckJanuvia, Janumet Xr | $15 | $35,22659 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,415 family providers in Alabama.
Other family in Auburn
- Molly ReevesAuburn$158K
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.